Zimbabwe has turned down a substantial US healthcare agreement worth $367m (£272m) over five years due to the United States' request for confidential data.
This move came to light following a internal memorandum dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government spokesman later explained that the United States was seeking biological samples for research and profit but refused to guarantee the resulting advantages from any future medical innovations.
"We are forced to start the difficult and regrettable process of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had furnished over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more negotiations to reach a deal agreeable to both sides so the nation's critical HIV programme can proceed.
Broader Background
This rejection comes after a similar situation in neighbouring Kenya, where a court suspended a related deal with the US after concerns were filed about the safety of Kenyans' health data.
After resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking government-to-government deals to enhance openness and accountability.
According to statements, 16 nations in Africa have to date agreed to similar health pacts, representing over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently on antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, without any equivalent promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"Put simply, our country would provide the basic resources for medical research without any assurance that the end products would be available to our population should a new disease outbreak arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one deals were upending structures previously established through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to deal with future global health emergencies.
"This mechanism is designed to guarantee that when a nation contributes its data, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to develop them."
These objections regarding the US deal "are not meant as opposition to America," he added.
"We encourage further dialogue with our US partners on how subsequent collaboration could be structured in a way that respects the independence and interests of each country."
Health Experts Reaction
A leading public health body said it acknowledged the government's concerns, but suggested that talks should continue given that a large portion of the country's HIV programmes were funded by external financing.
"Where specific concerns arise, such as those involving information security or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," it commented.
The situation underscores the ongoing challenges between accepting vital foreign assistance and safeguarding a country's data in an increasingly data-driven world.